Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of preoperative and postoperative adjuvant tislelizumab in the treatment of recurrent operable head and neck squamous cell carcinoma after radiotherapy

Next Previous
Trial Profile

Clinical study of preoperative and postoperative adjuvant tislelizumab in the treatment of recurrent operable head and neck squamous cell carcinoma after radiotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Cisplatin; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Jul 2024 New trial record
  • 04 Jun 2024 Results assessing the efficacy and safety of neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent HNSCC after radiotherapy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top